Madrid on 27 December 2021, Roshe in Spain, headquarters of multinational pharmaceutical industry.
Christina Arius | Cover | Getty images
Swiss pharmaceutical legend Rush On Wednesday, it said that it signed a deal of $ 5.3 billion to develop the Danish Biotech Zelarland Pharma’s obesity drug candidate, as both firms want to compete in the weight loss drug market.
The deal will be seen as a standalone therapy of two companies as a standalone therapy of co-development and co-commercial patriarchal, Zelarland Pharma, as well as a certain combination with the lead insitin asset CT-388 of Rosha.
Under the agreement, Zealand Pharma will receive an advance cash payment of $ 1.65 billion, with the capacity of paying milestones up to $ 5.3 billion up to $ 5.3 billion, based on phase -3 tests and sales development, Rosha said in a statement.
Soon after the announcement, Jaeland Pharma shares jumped 29%, and were trading up to 27% by 11:25 pm at London, while Roshe added 5.4%.
Obese veterans shares Novo nordiskMeanwhile, 3.9% slipped during Wednesday session Ellie lily 1.5% drowned in pre-market trade.
Zeeland Pharma CEO and Chairman Adam Stansburg told CNBC that the deal showed two companies “in future obesity space showing a strong commitment to lead to obesity.”
STANTGEGG said that the company had received “high level interest” since the company started a partnership discussion last year. However, he noted that Rosh “was the most desirable so far,”, cited the prior development of the Swiss firm in the obesity market, GLP -1, including its acquisition of manufacturer carmot theraputics.
“Roshe has assured us that he has an ambition to lead in this medical space,” STANTGG on Wednesday told CNBC via video calls.
He said that the firm was unlikely to partner with market leaders Novo or Lily, respectively focused on the current GLP -1 obesity drug franchise Vegovi and Zapebound.
Bank of America Securities said in a note on Wednesday that Roche partnership “GLP -1S and Emilin Mechanism was the best case landscape for Zealand”, given their current work in both GLP -1S and Emilin Mechanism.
It is expected to be closed in the second quarter, which will commercially view the RORSH and Zealand to jointly in the US and Europe, with two sharing benefits and disadvantages based on 50/50. Rosh, meanwhile, will gain exclusive commercialization rights in the rest of the world.
Next generation weight loss drugs
Eeland Pharma has long indicated amilin analogs as the “next generation” of the treatment of weight loss. They work by mimicking a hormone that is co-condied with insulin in the pancreas to increase thirdity. It differs from GLP-1 agonist, which mimics the incarnated incurin hormone produced in the intestine to press the appetite and regulate blood sugar.
“Unlike GLP-1s, who lose hunger to people, Petrilintide can help people feel faster,” STANTGEGR said.
I am a passionate digital marketer, content writer, and blogger. With years of experience in crafting compelling content and driving digital strategies. I’m always exploring new trends, optimizing strategies, and creating content that resonates with audiences. When I’m not working, you’ll find me diving into the latest digital marketing insights or experimenting with new blogging ideas.